Jim Simons Eagle Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 256,350 shares of EGRX stock, worth $166,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares

256,350

Previous 244,250 4.95%

Holding current value

$166,627

Previous $1.37 Million 30.43%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$3.71 - $6.07 $44,891 - $73,447	12,100 Added 4.95%	256,350 $951,000
Q2 2024 Aug 09, 2024	SELL	$3.34 - $5.6 $299,264 - $501,759	-89,600 Reduced 26.84%	244,250 $1.37 Million
Q1 2024 May 13, 2024	BUY	$4.26 - $6.51 $167,844 - $256,494	39,400 Added 13.38%	333,850 $1.75 Million
Q4 2023 Feb 13, 2024	BUY	$4.63 - $15.21 $177,319 - $582,512	38,298 Added 14.95%	294,450 $1.54 Million
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $65,722 - $98,864	-4,321 Reduced 1.66%	256,152 $4.04 Million
Q2 2023 Aug 11, 2023	BUY	$17.74 - $31.87 $915,792 - $1.65 Million	51,623 Added 24.72%	260,473 $5.06 Million
Q1 2023 May 12, 2023	SELL	$25.06 - $34.09 $1.45 Million - $1.97 Million	-57,800 Reduced 21.68%	208,850 $5.93 Million
Q4 2022 Feb 13, 2023	SELL	$24.98 - $39.77 $190,572 - $303,405	-7,629 Reduced 2.78%	266,650 $7.79 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $562,746 - $1 Million	21,300 Added 8.42%	274,279 $7.25 Million
Q2 2022 Aug 12, 2022	BUY	$41.26 - $51.35 $1.63 Million - $2.02 Million	39,400 Added 18.45%	252,979 $11.2 Million
Q1 2022 May 13, 2022	BUY	$44.58 - $52.6 $258,564 - $305,080	5,800 Added 2.79%	213,579 $10.6 Million
Q4 2021 Feb 11, 2022	BUY	$45.82 - $56.9 $252,010 - $312,950	5,500 Added 2.72%	207,779 $10.6 Million
Q3 2021 Nov 12, 2021	BUY	$43.79 - $55.78 $236,466 - $301,212	5,400 Added 2.74%	202,279 $11.3 Million
Q2 2021 Aug 13, 2021	SELL	$36.86 - $44.5 $287,508 - $347,100	-7,800 Reduced 3.81%	196,879 $8.43 Million
Q1 2021 May 13, 2021	SELL	$40.32 - $50.97 $907,200 - $1.15 Million	-22,500 Reduced 9.9%	204,679 $8.54 Million
Q4 2020 Feb 10, 2021	SELL	$41.72 - $51.34 $2.45 Million - $3.02 Million	-58,821 Reduced 20.57%	227,179 $10.6 Million
Q3 2020 Nov 13, 2020	SELL	$37.02 - $51.28 $2.35 Million - $3.26 Million	-63,500 Reduced 18.17%	286,000 $12.1 Million
Q2 2020 Aug 13, 2020	BUY	$43.24 - $55.02 $2.63 Million - $3.35 Million	60,900 Added 21.1%	349,500 $16.8 Million
Q1 2020 May 14, 2020	BUY	$34.37 - $60.07 $4.53 Million - $7.92 Million	131,900 Added 84.17%	288,600 $13.3 Million
Q4 2019 Feb 13, 2020	BUY	$54.32 - $64.31 $6.54 Million - $7.74 Million	120,400 Added 331.68%	156,700 $9.42 Million
Q3 2019 Nov 13, 2019	BUY	$53.25 - $59.98 $1.93 Million - $2.18 Million	36,300 New	36,300 $2.05 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.42M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $8.46M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account